Bach2 is a transcription factor required for affinity maturation of B cells. A recent study reveals, quite unexpectedly, that Bach2 also plays a key role in the pre-B cell receptor checkpoint and functions as a tumor suppressor in pre-B cell acute lymphocytic leukemia.
From lineage specification to the ultimate production of plasma cells, the B cell development program is not only marked by distinct phases of Ig rearrangement and diversification, but cell fate decisions are also often closely coordinated with the functional status of the surface B cell receptor (BCR). It is now generally accepted that B cell development is programmed with a series of checkpoints that control the initiation of key downstream events. The first major checkpoint, the pre-B cell receptor (pre-BCR) checkpoint, governs the transition from the pre-BI (completion of V H -DJ H rearrangement) to the pre-BII stage (onset of immunoglobulin [Ig] light chain rearrangement) (Herzog and Jumaa, 2012) . Structurally resembling a mature BCR, the pre-BCR signaling complex is formed between a productively rearranged Ig heavy chain (IgH), the invariant, surrogate light chain, and two accessory signaling molecules, Iga and Igb. Because V H -DJ H joining carries a great risk of disrupting the V segment open reading frame, the pre-BCR checkpoint is believed to function as a quality control step to monitor the structural integrity of the newly synthesized IgH chain on a pre-BI cell. Consequently, cells expressing nonfunctional pre-BCRs are either eliminated (negative selection) or allowed to rearrange the second IgH allele if still available. Cells equipped with a signaling competent pre-BCR are allowed to expand and proceed to the pre-BII stage, where Ig light chain rearrangement is initiated (positive selection).
Despite its importance in B cell development, regulation of the pre-BCR checkpoint remains incompletely understood. First, the transcription factor network operating at this checkpoint has yet to be defined. Second, it is not clear how signals from the pre-BCR are integrated into the cell fate decision in a manner that enables negative selection prior to positive selection. In a recent Nature Medicine article, Swaminathan et al. (2013) made exciting discoveries that shed light on both fronts. In searching for novel regulators of the pre-BCR checkpoint, the investigators honed in on Bach2 after analyzing relevant gene expression changes in both humans and mice.
Bach2 is a transcription factor previously implicated in Ig class switch recombination and efficient germinal center formation in mature B cells (Muto et al., 2004 Figure 1A ). The second major and novel conclusion from this study carries significant clinical implications. Swaminathan et al. (2013) proposed that BACH2 is a novel tumor suppressor in pre-B cell acute lymphocytic leukemia (pre-B ALL), a notion that enforces the general concept that pre-B cell checkpoint regulators often also play roles in pre-B ALLs. PAX5, BCL6, and another pre-B cell checkpoint regulator, SLP-65, have all been previously implicated in pre-B ALLs (Duy et al., 2011; Herzog et al., 2006; Mullighan et al., 2007) . The tumor suppressor function of BACH2 is supported by a large volume of results from cell culture-based experiments and genetic analysis of mouse and human pre-B ALLs, as well as clinical response data of pediatric B-ALL patients (Swaminathan et al., 2013) . The most striking experiment among many is a Myc transformation assay performed in a bone marrow transplantation setting, a test well-known to evoke the ARF/p53-enforced tumor suppressive barrier (Lowe et al., 2004) . Consistent with the ability of Bach2 to antagonize Mycinduced transformation, Myc-transduced Bach2 À/À pre-B cells gave rise to lethal leukemia within 3 weeks, while recipients of Myc-transduced, Bach2-proficient cells remained leukemia-free for up to 10 weeks. Clinical data from pediatric ALL patients demonstrated the ability of BACH2 expression to predict survival outcome (Swaminathan et al., 2013) . Specifically, at the time of diagnosis, loss of BACH2 expression strongly correlated with predicted minimal residual disease and lower relapse-free survival. Comparing matched sample pairs collected at initial diagnosis and subsequent relapse, the authors found loss of BACH2 expression to be a common feature of disease relapse. How could BACH2 expression or function be lost during pre-B ALL development? The authors presented four possible scenarios, each supported by evidence from primary human ALL samples. These include a hot spot mutation in the BTB domain of BACH2 (found in five of ten Ph + ALL cases), promoter hypermethylation, PAX5 inactivation, and deletion of 6q15, where the human BACH2 gene resides. Of note, in three out of four 6q15 deletion cases examined, the deletion was an acquired event at relapse. Combined with a general reduction of BACH2 mRNA in all relapsed cases, this observation raises the distinct possibility that leukemia subclones with low BACH2 were more resistant than subclones with higher BACH2 expression to standard ALL treatment. This notion is in line with the differential toxicity of TKI in BCR-ABLtransformed wild-type and Bach2 À/À pre-B cells. Because BACH2 and BCL6 play opposing roles in p53 regulation, checkpoint control, and patient outcome ( Figure 1B) , the authors propose to pharmacologically inhibit BCL6 using the BCL6 peptide inhibitor RI-BPI (Duy et al., 2011; Polo et al., 2004) in order to restore p53 expression and hence therapeutic response.
The study by Swaminathan et al. (2013) In addition, at least under certain circumstances, Bach2 can shuttle between the cytoplasm and nucleus in a redox sensitive fashion Muto et al., 2002) . Therefore, is Bach2 subcellular localization modulated during the pre-BCR checkpoint? Since Bach2 has emerged as a key regulator of the pre-BCR checkpoint, these issues merit future studies.
The effectiveness of cancer therapeutics targeting signal transduction pathways is comprised of a diversity of mechanisms that drive de novo or acquired resistance. Two recent studies identify mTOR activation as a point of convergence of mechanisms that cause resistance to inhibitors of the Raf-MEK-ERK and PI3K signaling.
A critical turning point in the fight against advanced and metastatic melanomas occurred just over a decade ago with the discovery and characterization of the BRAF activating mutation V600E in about 60% of melanomas (Davies et al., 2002 Chapman et al., 2011; Flaherty et al., 2012; Hauschild et al., 2012) . Despite the clinical success of these inhibitors, resistance has limited their long-term clinical impact. Although patient selection based on BRAF mutation status defines the patient population that would benefit from Raf or MEK inhibition, 20%-50% of patients showed no initial response, suggesting de novo resistance in a significant subset of melanoma patients (Chapman et al., 2011; Hauschild et al., 2012) . Furthermore, even for patients who do respond initially, within three months, essentially all suffer from relapsed tumors that have acquired drug resistance. This has led to numerous studies that have identified multiple mechanisms of de novo and/or acquired resistance to Raf, inhibition with mechanisms that cause ERK reactivation downstream of the inhibitor block, as well as ERK-independent mechanisms (Sullivan and Flaherty, 2013) . Corcoran et al. (2013) have recently identified a mechanism that may provide a more unifying model for the diverse mechanisms already identified. Although decreased phosphorylation of ERK (pERK) has thus far been the standard used to gauge tumor sensitivity in both clinical and preclinical studies, Corcoran et al. (2013) found that robust inhibition of pERK was still observed in melanoma
